Photo by sxy_selia from unsplash
Naturalistic and small randomized trials have suggested that pharmacogenetic testing may improve treatment outcomes in depression, but its cost‐effectiveness is not known. There is growing enthusiasm for personalized medicine, relying… Click to show full abstract
Naturalistic and small randomized trials have suggested that pharmacogenetic testing may improve treatment outcomes in depression, but its cost‐effectiveness is not known. There is growing enthusiasm for personalized medicine, relying on genetic variation as a contributor to heterogeneity of treatment effects. We sought to examine the relationship between a commercial pharmacogenetic test for psychotropic medications and 6‐month cost of care and utilization in a large commercial health plan.
Journal Title: Depression and Anxiety
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!